TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01223651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two step hyperinsulinaemic glucose clamp study.
Description: Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two step hyperinsulinaemic glucose clamp study.
Description: Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
Study: NCT04399863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETOILE therapeutic education
Description: ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
Study: NCT03462017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR247799
Description: Pharmaceutical form:Capsule Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Capsule Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Pharmaceutical form:Encapsulated tablet Route of administration: Oral
Study: NCT04567225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid and electrolytes replacement
Description: The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
Study: NCT00907777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK 1024850A
Description: One dose of vaccine will be injected intramuscularly into the deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)
Description: One dose of vaccine will be injected intramuscularly into the deltoid.
Study: NCT03462017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: Pharmaceutical form:Solution Route of administration: Transdermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Pharmaceutical form:Solution Route of administration: Transdermal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine
Description: Pharmaceutical form:Solution Route of administration: Transdermal
Study: NCT01900171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Study: NCT02402244

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo cytology specimen collection
Study: NCT03516708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Description: Standard of care
Study: NCT03897686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrous biopolymer with silver ions Argiform
Description: 2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 2 once-weekly intra-articular injections of saline solution 4 ml
Study: NCT02402244

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo medical data review
Study: NCT00316225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
Study: NCT04779567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1 gr iv 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml saline 0.9% iv 4 times a day
Study: NCT04410562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
Study: NCT02490995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movie
Description: Besides the anesthesist explanations the children will have a movie explanation.
Study: NCT03286829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesomet High dose in fasted condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet High dose in fasted condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesomet Low dose in fasted condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study: NCT03948763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V941
Description: V941 administered IM, Q3W for 9 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V941
Description: V941 administered IM, Q3W for 9 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V941
Description: V941 administered IM, Q3W for 9 3-week cycles
Study: NCT02551757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-titrating CPAP
Description: Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-CPAP
Description: Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
Study: NCT02734940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted Fentanyl
Description: No changes to current practices, using unlimited narcotic medications intraoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duramorph
Description: This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
Study: NCT00911820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT03286829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study: NCT03948763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V941
Description: V941 administered IM, Q3W for 9 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V941
Description: V941 administered IM, Q3W for 9 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, IV for 35 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, IV for 35 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, IV for 35 3-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, IV for 35 3-week cycles
Study: NCT05137106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Dry Needling
Description: All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry needling
Description: All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
Study: NCT03286829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesomet High dose in fed condition
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Study: NCT01200407

Intervention type: DRUG
Intervention: Amlodipine + Olmesartan medoxomil
Description: start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
Study: NCT04488484

Intervention type: OTHER
Group type: OTHER
Intervention: Serology test follow-up
Description: The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.).
Study: NCT03630627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB26
Description: SB26 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB26
Description: SB26 administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously
Study: NCT03075540

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Genetic Counseling and Testing YouTube Video
Description: Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
Study: NCT00902408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein enriched eggs
Description: 1 year of daily enriched lutein eggs or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lutein enriched eggs
Description: 1 year of daily enriched lutein eggs or placebo
Study: NCT01652898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDLA202
Description: Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONO LDL50
Description: Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol hydrochloride
Description: Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study: NCT00023634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: 100 mcg w/EGFRvIII

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: arm 1: 100 mcg w/EGFRvIII
Study: NCT01338766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression using the iO-Flex® system
Description: Decompression using the iO-Flex® system
Study: NCT04068662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pregnant Moms' Empowerment Program
Description: The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nondirective Support Group
Description: Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
Study: NCT05169749

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control-Service Nurse Group
Description: Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nursing Visiting Group
Description: Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery.
Study: NCT04047940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900020
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900020
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900020
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Administered orally
Study: NCT03867006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and Carbohydrate
Description: In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
Study: NCT00218465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW468816
Description: Pharmacotherapies for Relapse Prevention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Study: NCT02345681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study: NCT04214054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moldable self-hardening biphasic calcium phosphate graft
Description: Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No graft material placed - Blood Clot only
Description: A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
Study: NCT01120301

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp